Get App

Takeda proposes sale of Shire drug to gain European approval

The Japanese drug developer said it had proposed divesting Shire's pipeline compound SHP647, which is currently in Phase III clinical trials, along with some associated rights.
  • Published On Oct 29, 2018 at 02:00 PM IST
Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

The Japanese drug developer said it had proposed divesting Shire's pipeline compound SHP647, which is currently in Phase III clinical trials, along with some associated rights.

It said it did not expect the issue to delay its closing of the takeover of Shire and was the only issue it was discussing with European Union regulators after receiving approvals in China and Japan for the deal.
  • Published On Oct 29, 2018 at 02:00 PM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App